Drug resistance in cancer: molecular evolution and compensatory proliferation.
about
Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein.Computer simulations of the signalling network in FLT3 +-acute myeloid leukaemia - indications for an optimal dosage of inhibitors against FLT3 and CDK6.A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.The organic ester O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate dihydrochloride attenuates murine breast cancer growth and metastasis.
P2860
Drug resistance in cancer: molecular evolution and compensatory proliferation.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@en
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@nl
type
label
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@en
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@nl
prefLabel
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@en
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@nl
P2860
P356
P1433
P1476
Drug resistance in cancer: molecular evolution and compensatory proliferation.
@en
P2093
Ran Friedman
P2860
P304
11746-11755
P356
10.18632/ONCOTARGET.7459
P407
P577
2016-02-17T00:00:00Z